GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

Global health concerns escalated Monday as the U.S. Centers for Disease Control and Prevention reportedly halted collaboration with the World Health Organization, coinciding with the discovery of ...

The gun used in a fatal Nashville school shooting was purchased in Arizona, police said on Thursday afternoon. On Wednesday morning, 17-year-old Solomon Hendersen opened fire in Antioch High ...

Split Fiction is the newest game coming from Hazelight Studios, the minds behind the revolutionary co-op title It Takes Two and it's releasing in a few weeks! That's right, after making the go-to ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

Andy Biggs wants to abolish OSHA oversight nationwide Arizona says GlaxoSmithKline's greed endangered kids with asthma 500 active-duty soldiers from the 10th Mountain Division to deploy in Arizona ...

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

reflecting a similar trajectory to GSK’s complete exit from Haleon in May 2024. These moves underline the companies’ attempts to redefine their post-split identities. Haleon’s strong market ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.